Table 2.

Diagnostic and prognostic impact of AKR1B10 levels in HCC.

Study Sample	Main Findings	Prognosis 1	Reference
168 HCCs with viral and non-viral etiology	AKR1B10 overexpression associated with lower pT-classification Loss of AKR1B10 correlated with increased proliferative activity Poorer prognosis in patients with AKR1B10-negative HCCs compared with patients with AKR1B10- positive HCCs	Favorable	[24]
48 HCC with hepatitis C virus (HCV)	≥6% up-regulation of AKR1B10 associated with ≥21-fold relative risk of HCC	Poor	[34]
255 HCCs with viral and non-viral etiology	High AKR1B10 expression independently predicted longer RFS 2 and longer disease-specific survival.	Favorable	[32]
109 HCCs with viral and non-viral etiology	AKR1B10 expression associated with free surgical margins, early BCLC 3 staging, and lack of metastasis Higher AKR1B10 expression associated with better OS 4, progression-free survival, and lower metastatic risk	Favorable	[28]
26 HCC with viral and non-viral etiology	Lower AKR1B10 expression was associated with worse RFS and OS.	Favorable	[30]
43 HCC with HCV	High AKR1B10 expression independently predicted HCC. 5-year cumulative incidences of HCC were 22.8% and 2.2% in patients with high and low AKR1B10 expression, respectively.	Poor	[35]
8 HCC with HCV	High AKR1B10 expression was the only independent risk factor for HCC. 5-year cumulative incidences of HCC were 13.7% and 0.5% in patients with high and low AKR1B10 expression, respectively.	Poor	[36]
13 HCC with HBV	High AKR1B10 expression independently predicted HCC. 5-year cumulative incidences of HCC were 20.6% and 2.6% in patients with high and low AKR1B10 expression, respectively.	Poor	[38]
110 HCC with HBV	Higher AKR1B10 expression associated with higher DFS 5 and OS and low risk of early HCC recurrence	Favorable	[31]

¹ Based on high AKR1B10 levels; ² RFS: recurrence-free survival; ³ BCLC: Barcelona Clinic Liver Cancer; ⁴ OS: overall survival; ⁵ DFS: disease-free survival.